Rocuronium Bromide Injection, Solution
Product Images NDC 51662-1355

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 51662-1355). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mL Vial Label (10 mL Vial Label)

Label for Rocuronium Bromide Injection 10 mg/mL in a 10 mL multiple dose vial. The label indicates it is for intravenous use only and prescription use. Includes a warning about respiratory depression and the need for artificial respiration facilities. Manufactured by Hospira, Inc., Lake Forest, IL. The label also shows an NDC and contains storage instructions and barcode.*

FDA Label Image

51662 1355 1 Vial Labeling Updated

Label for Rocuronium Bromide Injection 10 mg/mL multiple dose vial by HF Acquisition Co LLC, DBA HealthFirst. The label includes a warning for paralyzing agent and instructions for intravenous use only. The label also features storage and dosage warnings and displays an NDC code area.*

FDA Label Image

C1 (Clinical Pharm 1)

A data table showing intubation effectiveness for Rocuronium Bromide administered over 5 seconds. It compares dose in mg/kg, percent of patients with excellent or good intubating conditions, and time to completion of intubation (minutes) across three age groups: adults 18 to 64 years, infants 3 months to 1 year, and pediatric 1 to 12 years. Higher doses and younger age groups show 100% success and shorter intubation times.*

FDA Label Image

C2 (Clinical Pharm 2)

Data table presenting Rocuronium Bromide dosing by age group: Adults 18 to 64 years, Geriatric ≥65 years, Infants 3 months to 1 year, and Pediatric 1 to 12 years. The table includes dose in mg/kg administered over 5 seconds, time to ≥80% block, time to maximum block, and clinical duration in minutes with ranges.*

FDA Label Image

C10 (Clinical Pharma 10)

A data table presenting pharmacokinetic (PK) parameters of rocuronium bromide across different patient age ranges from birth to 17 years. It includes clearance (CL), volume of distribution, and half-life (t1/2 β) with mean values and standard deviations for each age group.*

FDA Label Image

C3 (Clinical Pharma 3)

A data table showing Rocuronium Bromide dose response by age group following intravenous administration over 5 seconds. It lists doses in mg/kg for neonates, infants, toddlers, children, and adolescents with corresponding time to maximum block and time to reappearance T3 values, including ranges and sample sizes for each group.*

FDA Label Image

C4 (Clinical Pharma 4)

A box plot chart showing the time to 80% or greater block versus initial dose of Rocuronium Bromide by age group. It presents median, 25th and 75th percentiles, and individual values for three age groups: 18-64 years, 65 years and older, and 1-12 years, with doses ranging approximately from 0.45 to 1.2 mg/kg on the x-axis and time in minutes on the y-axis.*

FDA Label Image

C5 (Clinical Pharma 5)

A box plot graph titled 'Duration of Clinical Effect vs. Initial Dose of Rocuronium Bromide by Age Group,' showing the median, 25th and 75th percentiles, and individual values of effect duration in minutes on the vertical axis for different age groups and doses measured in mg/kg on the horizontal axis.*

FDA Label Image

C6 (Clinical Pharma 6)

A line graph titled 'Duration of Clinical Effect vs. Number of Rocuronium Bromide Maintenance Doses, by Dose.' The x-axis represents the dose number from 0 to 6, and the y-axis represents the duration in minutes from 0 to 30. Two dose levels are shown: 0.10 mg/kg with 29 subjects and 0.15 mg/kg with 13 subjects. The graph shows increasing duration of clinical effect over repeated doses for both doses, with the higher dose showing greater duration.*

FDA Label Image

C7 (Clinical Pharma 7)

A pharmacokinetic (PK) parameters data table comparing Adults (ages 27 to 58 years) and Geriatrics (≥65 years). It includes values for Clearance (L/kg/hr), Volume of Distribution at Steady State (L/kg), and t1/2 β Elimination (hr) with means and standard deviations in parentheses.*

FDA Label Image

C8 (Clinical Pharma 8)

A data table presenting pharmacokinetic parameters of rocuronium bromide, showing clearance, volume of distribution at steady state, and elimination half-life (t1/2 β) in normal renal and hepatic function, renal transplant patients, and hepatic dysfunction patients, with values and standard deviations.*

FDA Label Image

C9 (Clinical Pharma 9)

A data table showing pharmacokinetic parameters of Rocuronium Bromide in patients of different age ranges (3 to <12 months, 1 to <3 years, and 3 to <8 years). The table lists Clearance (L/kg/hr), Volume of Distribution at Steady State (L/kg), and t1/2 β Elimination (hr) with mean values and standard deviations for each age group.*

FDA Label Image

Dosage 1 (Dosage And Administration 1)

A data table showing infusion delivery rates (in mL/hr) for Rocuronium Bromide Injection, Solution at 10 mg/mL, corresponding to various patient weights (kg and lbs) and drug delivery rates (mcg/kg/min). The table cross-references patient weight in kilograms and pounds with drug delivery rates ranging from 4 to 16 mcg/kg/min, providing specific infusion rates for clinical dosing calculations.*

FDA Label Image

Dosage 2 (Dosage And Administration 2)

A data table showing infusion delivery rates in mL/hr for various patient weights in kilograms and pounds. The table provides drug delivery rates ranging from 4 to 16 mcg/kg/min, with corresponding infusion rates for patient weights from 10 kg to 100 kg. The table is intended for dosing calculations.*

FDA Label Image

Dosage 3 (Dosage And Administration 3)

A dosage calculation table showing infusion delivery rates in mL/hr for ROCURONIUM BROMIDE injection, solution at various patient weights ranging from 10 to 100 kg (22 to 220 lbs). It correlates drug delivery rates in mcg/kg/min from 4 to 16 with corresponding infusion rates.*

FDA Label Image

Highlights (Highlights)

A data table listing sections of a medical document related to Rocuronium Bromide, including Important Dosing and Administration Information (2.1), Dosage and Administration Dosage in Specific Populations (2.6), Warnings and Precautions for Risk of Death due to Medication Errors (5.3), and Warnings and Precautions for Residual Paralysis (5.5), along with their respective update dates from 2017 and 2018.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Label (Serialized 10 mL Vial Label)

Rocuronium Bromide 10 mg/mL injection solution vial with yellow top labeled "Paralyzing Agent." The multi-dose 10 mL vial includes a barcode and an orange label indicating it is for intravenous use only, distributed by HF Acquisition Co LLC.*

FDA Label Image

Serialized Vial Labeling 51662 1355 1 Update

Rocuronium Bromide 10 mg/mL injection solution vial with a yellow cap labeled "Paralyzing Agent." The vial contains 10 mL multiple dose vial. The label shows it is for intravenous use only and is distributed by HF Acquisition Co LLC, DBA HealthFirst in Mukilteo, WA. The vial bears a barcode and QR code on a white label.*

FDA Label Image

Structure (Structure)

Chemical structure of rocuronium bromide, showing the molecular framework including rings, functional groups, and the bromide ion associated with the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.